J. B. CHEMICALS & PHARMACEUTICALS LIMITED

J. B. Chemicals & Pharmaceuticals Limited

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 12:08:03 2024-04-29 am EDT			5-day change	1st Jan Change
1,869 ^INR	+0.28%		+4.69%	+15.11%

Apr. 08	J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as A Non-Executive, Non-Independent Director	CI
Mar. 22	J. B. Chemicals & Pharmaceuticals Limited Receives Order from Assessment Unit, Income Tax Department	CI

J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24

February 06, 2024 at 05:12 am EST

The Board of directors of the J. B. Chemicals & Pharmaceuticals Limited at its meeting held on February 6, 2024 has declared interim dividend of INR 5.50 per equity share of face value of INR 1 (550%) for financial year 2023-24. The dividend will be remitted/dividend warrants will be despatched on February 28, 2024.

Latest news about J. B. Chemicals & Pharmaceuticals Limited

J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as A Non-Executive, Non-Independent Director	Apr. 08	CI
J. B. Chemicals & Pharmaceuticals Limited Receives Order from Assessment Unit, Income Tax Department	Mar. 22	CI
J. B. Chemicals & Pharmaceuticals Limited Announces Demise of Ranjit Shahani, Chairman and Non-Executive, Independent Director	Mar. 09	CI
KKR Reportedly Considers Selling Controlling Stake in JB Pharma	Feb. 28	CI
Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,000 From INR1,970, Keeps at Buy	Feb. 08	MT
JB Chemicals' Consolidated Profit Climbs in Fiscal Q3; Shares Jump 4%	Feb. 07	MT
J.B. Pharma Seeks Acquisitions	Feb. 07	CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 07, 2024	Feb. 07
J. B. Chemicals & Pharmaceuticals Appoints CFO	Feb. 06	MT
JB Chemicals Names CFO	Feb. 06	MT
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand	Feb. 06	RE
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 06	CI
J. B. Chemicals & Pharmaceuticals Limited Appoints Narayan Saraf as the Chief Financial Officer, with Effect from February 23, 2024	Feb. 06	CI
J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24	Feb. 06	CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited - Shareholder/Analyst Call	Dec. 22
J. B. Chemicals & Pharmaceuticals Limited Announces Execution of Trade Mark License Agreement with Novartis Innovative Therapies Ag and Promotion & Distribution Agreement with Novartis Healthcare Private Limited	Dec. 19	CI
JB Pharma Seeks Acquisitions	Nov. 24	CI
Jefferies Adjusts J.B. Chemicals & Pharmaceuticals' Price Target to INR1,680 From INR1,555, Keeps at Buy	Nov. 09	MT
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 08, 2023	Nov. 08
J.B. Chemicals Records Rise in Fiscal Q2 Consolidated Net Profit	Nov. 08	MT
J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as an Additional Director	Nov. 07	CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
J.B. Chemicals' CFO Resigns	23-09-07	MT
J. B. Chemicals & Pharmaceuticals Limited Announces Cessation of Lakshay Kataria, Chief Financial Officer and Key Managerial Personnel, Effective November 30, 2023	23-09-07	CI
J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2023	23-08-25	CI

Chart J. B. Chemicals & Pharmaceuticals Limited

Duration

Period

Chart J. B. Chemicals & Pharmaceuticals Limited

More charts

Company Profile

J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.

Sector

Pharmaceuticals

Calendar

2024-05-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for J. B. Chemicals & Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,864 INR

Average target price

1,882 INR

Spread / Average Target

+0.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
J. B. CHEMICALS & PHARMACEUTICALS LIMITED	+15.11%	3.47B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals